AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas (“CPRIT”). CPRIT was established to expedite innovation and commercialization in the area of cancer research and to enhance access to evidence-based prevention programs and services throughout the State. Acceptance of the award is subject to the completion of due diligence and contract negotiations.
